Job Title

Apellis MSL (Medical Science Liaison)Remote role based in NSW, focused on developing and maintaining peertopeer scientific relationships with key medical experts in NSW and QLD. This role primarily supports the Apellis ophthalmology program within the Medical Affairs department.SummaryThe role involves collaborating with ophthalmologists and other eye care professionals to support the medical strategy and ensure dissemination and discussion of uptodate medical information based on scientific exchange.Roles and ResponsibilitiesDevelop and maintain peertopeer collaborations and relationships with key medical experts in the ophthalmology communitySupport medical affairs (e.g., scientific exchange, conference support) and clinical development initiatives (e.g., site identification, trial recruitment)Collaborate with physicians on medical affairs initiatives including publications, advisory boards, medical education opportunities, and trainingServe as scientific peertopeer resource to external disease experts and internal stakeholdersProvide the medical community with uptodate medical information, robust disease expertise, and product informationCommunicate clinical insights on new data to Apellis Medical Affairs and inform medical strategy for the therapeutic areaTrain internal stakeholders on key scientific and medical topics in the relevant therapeutic areaDevelop an understanding of the regional landscape including specialties involved in patient careMaintain effective and appropriate communication among internal stakeholders while maintaining full compliance with relevant requirementsGenerate tactical regional plans to provide needsbased, valueadded support of the medical and scientific community in line with company goalsUse systems to strategically map, identify, profile and prioritize thought leaders in line with the medical plan and goalsMaintain accurate reporting and documentation of MSL activitiesCollaborate with internal crossfunctional stakeholders (e.g., Commercial, Market Access)Education, Registration & CertificationTertiary qualification in health or medical science (MD, PhD, BPharm, BOptom, Borth, BSc); postgraduate studies highly desirable (e.g., Master''s or PhD)ExperienceAt least 13 years of experience in Medical Affairs or Medical Science with a high level of scientific and business acumenComprehensive understanding of, and the ability to continue to learn and disseminate information about, the responsible disease area(s)Prior ophthalmology experience with knowledge of market dynamics in Australia (and New Zealand) and established relationships with eye care professionals is mandatoryUnderstanding of compliance considerations and ability to work compliantly in a fieldbased role, within the medical organization and across the commercial organizationThorough and current knowledge of the Medicines Australia Code of ConductSkills, Knowledge & AbilitiesExcellent oral and written communication skillsEnergetically embraces responsibilities and demonstrates the ability to achieve goalsStrong initiative and functions well as part of a crossfunctional teamExcellent timemanagement and planning skillsAbility to work independently and manage time effectively while travelingProactive mindset with the ability to shape internal processes and contribute beyond the core job scope when opportunities ariseProactive team player, flexible, and able to work in a dynamic environmentTravel RequirementsRegular travel within NSW and Queensland to engage with healthcare professionals and key stakeholdersOccasional travel to national and international congresses and meetings may be requiredMust hold a valid driver''s licence and have access to reliable transport for regional travelBenefits and PerksApellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!Company BackgroundApellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop lifechanging therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the firstever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary ICMPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.For more information, please visit or follow us on LinkedIn and X.#J-18808-Ljbffr